МОЗ РК і "АстраЗенека" підписали дорожню карту за проєктом контрактного виробництва

Investment of 350 million EUR in state-of-the-art research infrastructure is Boehringer Ingelheim’s largest single investment in Germany to date Boehringer Ingelheim strengthens innovation power and development of biopharmaceuticals, which account…

On June 17-18, Kyiv hosted a remarkable popular science event dedicated to science for the victory and reconstruction of Ukraine. Our R&D scientists of YURiA-PHARM had the opportunity to share…